Elevated APE1 expression in cancer cells has been associated with poor response to mono-alkylating agents[91,149-151], whereas various approaches to reduce APE1 activity were shown to increase cancer cell sensitivity to temozolomide[149,152-158]. The gene discussed is APEX1; the disease is cancer.